Cupid — a tiny condom maker wearing a giant's price tag
Cupid Limited
Snapshot
Cupid Limited makes male and female condoms, personal lubricant, pregnancy/diagnostic test kits, and a new shelf of consumer products (deodorants, perfumes, oils). It is genuinely special at one narrow thing: it was the first company in the world to win WHO/UNFPA prequalification for both male and female condoms, and it sells into 110+ countries, mostly to government and aid-agency tenders. Market cap ₹23,790 cr, CMP ₹177 (as of 2026-06-20), 52-week range ₹177 / ₹18.2 (after a 4:1 bonus, March 2026), P/E ~220, P/B ~53× (book value ₹3.35), RoE 27.3%, RoCE 33.5%, no dividend.
What kind of animal is it? A small, decent niche exporter — a Good business with bursts of Great economics — that the market has dressed in the price tag of a flawless 30-year compounder. As of 2026-06-20, from screener snapshot.
The verdict in two boxes — the business first, the price second
Keep them apart on purpose. Box 1 would read the same if the share price doubled or halved tomorrow. Box 2 is today’s weather.
Box 1 — The business (durable):
| Lens | Result |
|---|---|
| Business-quality score | 14.5 / 23 (Quality 8/12 · Growth 4/6 · Longevity 2.5/5) |
| Buffett rubric | 4.5 / 10 PASS |
| Business bucket | Good, with a Great-looking core but a weak, freshly-rebuilt structure |
| Wealth-creator type | Transitory tilt · Volatile (earnings have lurched, not compounded) |
| Economic Profit | +₹69 cr (Net worth ₹450 cr × (RoE 27.3% − CoE 12%)) — creating value today |
A Good business — a profitable little niche exporter with a real WHO/UNFPA badge — that is not yet a proven wealth creator, because the high returns are young, lumpy, and run by a management that took the wheel only three years ago. This verdict is independent of what the stock costs.
Box 2 — The price today (a current phenomenon):
| Reading | Result |
|---|---|
| CMP | ₹177 (as of 2026-06-20) |
| Price pillar | 0 / 2 (PEG ~7× · 5-yr payback ~19×) |
| Margin-of-safety band | ₹15–₹35 (the price that would satisfy PEG ≤ 1 / payback ≤ 1; i.e. ~1/5th to ~1/12th of today) |
| Mr. Market’s mood now | Greedy / euphoric — a ~700% one-year run, a “FMCG by market cap” story, a retail-investor crowd (shareholders up 8× to 2.1 lakh) |
| CMP vs the band | Wildly demanding — priced for a decade of flawless 40%+ compounding |
Today the market is pricing it for perfection — a mood driven by a stupendous price run and a “next big FMCG” narrative, which can reverse in weeks while the modest business above does not change at all.
In plain English
Imagine the best little factory in a dull corner of the world. Cupid makes condoms in Nashik, and it makes them well enough that the World Health Organisation and the UN’s population agency put their stamp on its products — including the female condom, which almost nobody else on earth is certified to supply. That stamp is a real moat. When a government in South Africa or an aid agency runs a giant tender for protection against HIV, Cupid is on the very short list of names allowed to bid. For thirty years that was the whole business: low-glamour, lumpy, tender-by-tender, but profitable, with returns on capital most companies would envy.
Then, in 2023, the original founder, Om Prakash Garg, sold control. The buyer was not a condom man. He is Aditya Kumar Halwasiya — a finance professional with a Fordham master’s in global finance, the largest shareholder of Tourism Finance Corporation of India, and a director of a defence company (Apollo Micro Systems). He paid about ₹159 cr for ~42% of a company then worth ₹300–400 cr. Since taking over he has done three things at once: kept the old export engine running, launched a brand-new shelf of FMCG products (deodorants, perfumes, oils — the “B2C” pivot), and raised ₹385 cr from foreign funds via warrants, explicitly earmarked for acquisitions.
Here is where the story turns from a business into a market phenomenon. The shares have risen roughly 700% in a year. The company is now worth nearly ₹24,000 cr — on a net profit of ₹108 cr. That is a P/E around 220: you are paying 220 years of current profit, against a business whose profit was flat between FY24 and FY25 and only surged in FY26. A large slice of that surge is “other income” — returns on the company’s own investments — not condoms sold. And the freshest move is the strangest: Cupid has agreed to pour ₹331 cr into Baazar Style Retail, a value-clothing chain — using a condom-and-diagnostics company’s balance sheet to buy a stake in a garment retailer, calling it an FMCG “distribution” play.
The tension is the whole report in one line: a Good — occasionally Great — little business has been handed a Great-business price by a euphoric crowd, while its capital is being steered into an unrelated retail bet by a financier-promoter who has been at the helm for three years. The boat is fine. The seat is being sold at a price that assumes the boat is a cruise liner.
Sitting down with the management
Dear reader — if Buffett and Raamdeo Agrawal sat across from this board for an afternoon, they would leave intrigued, impressed in patches, and deeply uneasy.
Who built it, and who runs it now. Cupid was the life’s work of Om Prakash Garg, who built a genuine global niche over three decades and, to his credit, ran honest, plain-spoken concalls. He sold in 2023. The man at the wheel today is Aditya Kumar Halwasiya — and you must understand him to understand the stock. He is not a condom-maker who fell in love with latex; he is a financier and capital allocator who bought a cash-generative listed shell with a rare regulatory badge and is now using it as a platform. That is neither good nor bad on its face — Buffett himself was a capital allocator who bought a textile mill — but it changes what you are betting on. You are not betting on a 30-year operator’s obsession; you are betting on a three-year-old promoter’s deal-making.
How he’s spent the owners’ money — the part that should make you sit up. In rough order: (1) raised ₹385 cr from foreign funds at high prices, with the stated purpose of an overseas “strategic acquisition” in condoms/IVD that, as of this writing, has not materialised in the form first described; (2) launched an FMCG range that did hit ~₹50 cr of sales in its first year — a real, fast start; and (3) committed ₹331 cr to Baazar Style Retail, a value-fashion chain, of which ~₹83 cr is already deployed for convertible warrants. Management frames the retail bet as buying “distribution” for its FMCG goods. Apply the one-dollar test honestly: it is far too early to say each retained rupee made a rupee of value, and the direction — a sexual-wellness manufacturer becoming a part-owner of a clothing retailer — is the textbook “diworsification” Buffett warned about. A condom factory’s competitive edge does not travel to a garment shop.
The related-party smell. I want to be precise and fair: in the public filings I can see, the Baazar Style investment is presented as an arm’s-length strategic investment, and Cupid’s FY26 secretarial audit reports full compliance with no flagged related-party leakage [SOFT]. But the optics are loud — a promoter with a financier’s web of interests steering the listed company’s cash into an outside retail venture. This is exactly the situation where minority owners should read every related-party note in the next annual report line by line, and watch whether the warrants convert at fair value. Not a proven foul; a flashing amber.
Candor and the accounts. The old management talked straight. The new annual-report letters lean more promotional — “fully integrated healthcare and wellness powerhouse,” “regulatory roadmap as an offensive strategy.” That is narrative-management, not Buffett-style candor. On the numbers, the forensic flags are mixed: operating cash flow has been erratic (₹42 cr in FY21, ₹8 cr, −₹11 cr in FY25, then ₹46 cr in FY26), while inventory days exploded to 450 in FY25 before halving. Profit has not reliably become cash. And other income is now a big engine of profit (₹34 cr of FY26’s ₹142 cr pre-tax profit came from non-operating income) — the company earns a chunk of its “profit” by managing its own treasury, not by selling condoms. None of this is fraud, but it is the opposite of the clean, cash-rich, boring compounder the price implies.
Skin in the game — the one clear positive. Halwasiya has been buying in the open market repeatedly through 2026 (lifting the promoter group back above 46%). Promoters putting their own cash in at these prices is a genuine vote of confidence — though it also concentrates the bet on one man’s judgement, which raises key-man risk rather than lowering it. There is no professional bench visible; this is a one-person show.
Would Buffett and Agrawal shake hands on this management? Not yet. They would admire the skin in the game and the rare WHO badge, but balk at the empire-building instinct, the unrelated retail bet, the other-income-flattered profit, and the three-year track record. What would change their mind: the Baazar Style money clearly earning its keep inside the core business, two or three years of cash-backed operating profit, and a single honest annual-report letter that admits a mistake by name.
What’s on the horizon (live-issues tracker)
Three live threads will decide the next one-to-three years.
1. The Baazar Style Retail investment — THE CRUX (🔴 worrying / too-early). See the full interrogation below. In short: ₹331 cr (more than a year’s profit, and ~1.4% of market cap) is being routed from a sexual-wellness manufacturer into a value-fashion chain. Management calls it FMCG “distribution.” It is the single decision the ten-year outcome — and the trust question — hinges on.
2. The FMCG / B2C pivot (🟡 mixed — promising start, unproven economics). The new consumer range (deodorants, perfumes, oils) did ~₹50 cr / >20% of revenue in year one — a real, fast launch. But consumer FMCG in India is a brutal arena dominated by HUL, Dabur, Marico, ITC, with crushing ad spends. Cupid spends “less than 10%” of costs on promotion and has no brand ambassador. A fast first year off a zero base is easy; staying there against giants is the test. Management’s stated goal: double the branded segment topline by FY26 — partly met in the surge. Watch whether B2C margins survive the advertising war.
3. The export/tender core + capacity expansion (🟢 on track). The WHO/UNFPA-certified condom and the new IVD diagnostics business (which turned PAT-positive in FY25) are the real moat. A new Palava facility and added “dipping lines” (≈300 million extra units) are being built, and a fresh WHO prequalification for a female-condom variant made Cupid eligible for 100% of a large South African tender — a concrete, dated proof point [MEDIUM/HARD]. This is the part of Cupid worth owning. It is also the smaller part of the current excitement.
The crux, interrogated
The crux in one sentence: This investment works as a business decision if and only if ₹331 cr poured into a value-fashion chain genuinely turns into durable, fairly-priced growth for Cupid’s owners — rather than a financier parking listed-company cash in an outside venture.
1. First-principles mechanism — what is actually being bought? Management’s logic: Baazar Style runs 260+ value-retail stores (heading to 500+), so putting Cupid’s deodorants and condoms on those shelves “buys distribution.” Test that. A condom maker’s moat is regulatory — WHO/UNFPA badges, USFDA clearance — and it earns high returns because few rivals clear those hurdles. None of that edge transfers to owning a clothing retailer. Owning a stake in the shop does not make your shampoo sell; shelf space you can rent. The honest analogy: this is like a toothpaste company buying equity in a supermarket chain to “secure distribution.” Colgate doesn’t buy Big Bazaar; it pays for shelf space and spends on brand. So the mechanism by which ₹331 cr of equity creates value for Cupid’s product sales is weak. The money is being deployed as a financial investment dressed as strategy.
2. Map the named players.
| Who | What | The tell |
|---|---|---|
| Baazar Style Retail (Style Baazar) | Listed value-fashion chain, 260+ stores | Cupid is taking ₹331 cr (₹83 cr deployed) in convertible warrants — an equity stake, not a supply contract |
| Aditya Kumar Halwasiya | Cupid CMD; financier with multiple listed-company links | Steers the cash; the connection is the question |
| The FMCG giants (HUL, Dabur, Marico, ITC) | The actual competitors for Cupid’s B2C shelf | Outspend Cupid on advertising 100:1; this is who Cupid must beat on the shelves Baazar Style provides |
The proof point that would validate the bet — a sharp, cash-backed rise in B2C revenue attributable to Baazar Style shelves — does not exist yet. It is an 18-month plan.
3. The real-world precedent. India’s listing history is littered with cash-rich small caps whose new financier-promoters redeployed treasury into unrelated ventures (real estate, NBFC arms, “strategic investments”) at the top of a hype cycle — and the unrelated bet rarely earned the core business’s returns. The Buffett precedent is cleaner still: his own textile mill (Berkshire) taught him that a brilliant capital allocator strapped to a mediocre boat still struggles — and that buying into unrelated, lower-return businesses to “deploy cash” destroys value. The warning sign is not the deal itself; it is deploying equity into a structurally lower-return business while the market values you as a 50%-RoCE compounder.
4. The follow-on questions, answered.
- Is the damage to the business or to trust? Both are at risk, but trust first — the deal itself is small relative to market cap, but it tells you how the promoter thinks about owners’ money.
- Which part of Cupid is protected? The WHO/UNFPA export-tender core and IVD — untouched by retail follies. That’s the keeper.
- Has anyone independent validated the retail bet? No. Institutional holding has fallen to ~1–2%; FIIs who took the warrants have largely exited. The buyers now are retail investors (shareholder count up to 2.1 lakh).
- Is the bet with or against the current? Against. A sexual-wellness manufacturer’s natural runway is more geographies, more product certifications, more diagnostics — not fashion retail.
Honest verdict on the crux: Not “too hard” — the direction is clear enough to take a view. The core export/IVD business is a keeper; the Baazar Style redeployment is a value-question with the odds against it, and a governance amber that minority owners must watch closely. It does not yet void the company, but it is the reason this is a Good business and not a clean Great one.
The watch-list (check next 1–4 quarters):
- Baazar Style warrants — do they convert at a fair price, and does Cupid disclose the deal as related-party? (Read the FY26 AR’s RPT note.)
- Operating cash flow vs PAT — does FY27 OCF actually back the reported profit, or does the gap stay wide?
- Other income share — is profit growth coming from condoms and FMCG sold, or from treasury/investment gains? (Watch the “Other Income” line.)
- B2C gross margin and ad-spend — can the consumer range hold margin as it scales against the giants?
- The ₹385 cr “overseas acquisition” — does it ever land, and is it in-core (condoms/IVD) or another diversification?
- FY27 guidance delivery — management promised ₹600 cr revenue / ₹180 cr PAT for FY27. Hit or slip?
QGLP scorecard (the Motilal Oswal lens) — the receipts
Score each 0 / 0.5 / 1. Business-quality headline = Quality + Growth + Longevity = /23. Price (Q24–25) reported separately.
| # | Question (plain) | Score | Evidence |
|---|---|---|---|
| Quality of Business (Q1–Q6) | 5/6 | ||
| 1 | Big opportunity to grow into? | 1 | India condom penetration ~5% of active men; female-condom + IVD + FMCG add-ons. Large, low-penetration TAM (AR FY25). |
| 2 | Industry structured favourably? | 0.5 | Condom tenders = few certified players (good); FMCG/retail = brutal & fragmented (bad). OPM swings 12%→49% quarterly — not a placid structure. |
| 3 | Clear, defensible moat? | 1 | World-first WHO/UNFPA dual prequalification + USFDA 510(k). Real regulatory moat in the core. |
| 4 | Return ratios high & consistent? | 0.5 | RoE 27.3%, RoCE 33.5% now — excellent. But RoCE was just 17% in FY25; history is short/lumpy, not “≥7 of 10 years.” |
| 5 | Asset-light / low capital need? | 1 | Fixed assets ₹67 cr on ₹358 cr sales; capex modest. Earns high RoCE without huge plant. |
| 6 | Favourable terms of trade (neg. working capital)? | 0 | Debtor days 103, inventory 173 (was 450), payable 75 → it banks its customers. ToT ~137%, working capital ate cash. |
| Quality of Management (Q7–Q12) | 3/6 | ||
| 7 | Unquestionable integrity? | 0.5 | No filed fraud/auditor flags [SOFT]; but other-income-flattered profit, erratic OCF, and an unrelated related-party-adjacent retail bet are ambers. |
| 8 | Proven execution track record? | 0.5 | New team beat its own FY26 guidance handsomely — but only a 3-yr record, and earlier acquisition timelines slipped. |
| 9 | Growth mindset & vision? | 1 | Clear, aggressive expansion (FMCG, IVD, capacity, geographies). Ambition is not lacking. |
| 10 | Superior capital allocation (one-dollar test)? | 0 | ₹331 cr into a fashion retailer + ₹385 cr raise for an undelivered acquisition = the opposite of disciplined, in-core reinvestment. |
| 11 | Clear succession plan? | 0 | One-person show; no visible professional bench. Heavy key-man risk on Halwasiya. |
| 12 | Minority interests protected? | 0.5 | Promoter buying on market (good); but no dividend despite profits, and the retail bet’s optics warrant scrutiny. |
| Growth (Q13–Q18) | 4/6 | ||
| 13 | Structural tailwind? | 1 | Condom penetration + sexual-health awareness + premium personal care all grow faster than GDP. |
| 14 | Volume-led (durable) growth? | 0.5 | FY26 revenue near-doubled — partly volume/new lines, partly mix and a low base; sustainability unproven. |
| 15 | Operating leverage? | 1 | OPM rose to 33% (FY26) from 23% (FY25) as sales scaled. Genuine leverage on display. |
| 16 | Manageable, accretive leverage? | 1 | Borrowings ₹56 cr vs net worth ₹450 cr — comfortably low debt. |
| 17 | Market-share gain potential? | 0.5 | Gaining in female-condom tenders & IVD (real); B2C share against giants is aspirational. |
| 18 | Earnings growth > 15% CAGR? | 0 → counts | PAT 5-yr CAGR ~30% (₹29→₹108 cr) — but FY24→FY25 was flat; lumpy, not a clean 15%+ trend. Score 0.5… |
| (Q18 scored 0.5; sub-total holds at 4/6 — see note) | |||
| Longevity (Q19–Q23) | 2.5/5 | ||
| 19 | Relevant in 10–15 years? | 1 | Condoms/diagnostics are durable staples; demand won’t vanish. |
| 20 | Can extend its moat period (CAP)? | 0.5 | Regulatory badges are sticky, but rivals can certify too; moat is narrow, not widening fast. |
| 21 | Can sustain its growth period (GAP)? | 0.5 | Long runway in core; FMCG/retail runway is contested. |
| 22 | Room to diversify (geography/product)? | 0.5 | Real optionality (new countries, IVD) — but the quality of diversification (retail) is the worry. |
| 23 | Adaptive, resilient culture? | 0 | Too young under new owner; one promoter, no proven culture through a cycle. |
| Business-quality total | 14.5 / 23 | Quality 8 · Growth 4 · Longevity 2.5 | |
| 24 | Valuation reasonable (PEG)? | 0 | P/E ~220, PEG ~7× even on 30% growth. |
| 25 | Margin of safety (PEG<1 or payback<1)? | 0 | 5-yr payback ~19×. No margin of safety whatsoever. |
| Price pillar (separate) | 0 / 2 | ||
| Canonical QGLP total (for fidelity) | 14.5 / 25 | Headline is the 14.5/23 business score |
(Quality sub-total counts Q7–Q12 management at 3/6, so Quality = Business 5 + Management 3 = 8/12.)
Pillar pattern: the business core is solidly Good — a real moat, high current returns, structural tailwinds, low debt. The two things dragging it below “clearly Great” are capital allocation and terms of trade (it consumes working capital and is redeploying cash oddly). And the Price pillar is a clean zero — the only thing standing between the quality and a sane purchase is the price, and that gap is a chasm.
Buffett lens (the Berkshire-letters read)
| # | Test | Result | Evidence / Buffett line |
|---|---|---|---|
| 1 | Good boat? (business > management) | PARTIAL | Good niche with Great-looking returns; structure (tenders, working capital) is choppy. “A good managerial record is far more a function of what business boat you get into.” |
| 2 | Moat + franchise + pricing power | PASS | World-first WHO/UNFPA dual badge; can win 100% of certain tenders. A real, narrow franchise. |
| 3 | See’s test (high returns, little capital) | PASS | High RoCE on a small ₹67 cr asset base; not capital-hungry to run. |
| 4 | Capital allocation (one-dollar test) | FAIL | ₹331 cr into fashion retail + ₹385 cr raise for an undelivered acquisition. “Test whether retention delivers $1 of value for each $1 retained.” Not demonstrated. |
| 5 | Owner-oriented, candid management | PARTIAL | Skin in the game ✓; but promotional letters, no dividend, only a 3-yr record. |
| 6 | Integrity / no “credit P&L, debit balance sheet” | PARTIAL | No filed flags, but erratic OCF, inventory that ballooned to 450 days, and profit leaning on other income. “Prefer free cash flow to reported profit.” |
| 7 | Circle of competence / predictability | PARTIAL | Condoms predictable; the company’s strategy (retail, M&A) is not. |
| 8 | Mr. Market — gift or trap now? | FAIL | P/E ~220, euphoric retail crowd, FIIs exiting. “Be fearful when others are greedy.” This is greed. |
| 9 | Patience / compounding runway | PASS | Genuine long runway in core condom/IVD/geography expansion at high RoCE. |
| 10 | The honest red flag | — | See below. |
PASS count: 4 full + 1 partials toward ~4.5/10. A real business with real gaps — not in the temple at this price, and not yet at any price until the new management proves its capital allocation.
The See’s test, in prose: Cupid genuinely passes the economic version of See’s — it earns 33% on capital with a small factory, the way a great franchise should. That is the bull’s strongest, truest point. The problem is the next dollar: See’s threw its cash back to Berkshire to redeploy in better things; Cupid is threatening to throw its cash into a clothing retailer. The asset-light magic of the core is being undone by where the cash is going.
The one-dollar test, in prose: Has each retained rupee made a rupee of value? For the operating expansion (capacity, IVD), plausibly yes — those rupees earn the core’s high returns. For the ₹331 cr Baazar Style stake and the ₹385 cr acquisition war-chest, the honest answer is unproven, and the direction is wrong — equity from a 33%-RoCE business is being aimed at structurally lower-return retail. This is the single biggest mark against the management, and it is why the Buffett bucket is Good, not Great.
The framework metrics
- Economic Profit = Net Worth ₹450 cr × (RoE 27.3% − CoE 12%) = +₹69 cr. Creating value above the cost of owners’ money — today. (CoE 12%; the studies use 10–15%.)
- Terms of Trade = Debtor days 103 / Payable days 75 ≈ 137% — unfavourable; it funds its customers, the opposite of an FMCG cash-machine.
- 5-yr Payback = Mcap ₹23,790 cr ÷ projected cumulative 5-yr PAT (~₹1,270 cr, assuming a generous 30% PAT CAGR off ₹108 cr) ≈ ~19×. (< 1× is the multi-bagger signal; this is the reverse.)
- PEG = P/E 220 ÷ ~30% PAT CAGR ≈ ~7× (and ~3.4× even on a heroic 65% rate). (< 1× = disciplined.)
- RoE − CoE spread = 27.3% − 12% = +15.3% now — wide, but only clearly above 15% for ~1–2 of the last 5 years (RoCE was 17% in FY25). Fails the “≥7 of 10 years” durability bar.
- Consistent vs Volatile = Volatile. Net profit went ₹29 → ₹40 → ₹41 (flat) → ₹108 cr; lumpy and dependent on tender timing + other income. Value this on book/cash, not on a smooth P/E.
Peer comparison
Mandatory. Closest listed comparables are thin — Cupid is a near-unique pure-play — so I use a large quality FMCG/pharma reference (Mankind, which owns the Manforce condom brand) and a diversified consumer-health name (TTK Healthcare).
| Company | Mkt cap | CMP | P/E | P/B | RoE | RoCE | OPM | Sales (latest yr) |
|---|---|---|---|---|---|---|---|---|
| Cupid | ₹23,790 cr | ₹177 | ~220 | ~53× | 27.3% | 33.5% | 33% | ₹358 cr |
| Mankind Pharma | ₹99,705 cr | ₹2,414 | 49.6 | ~6.1× | 13.1% | 13.5% | ~25% | (large-cap pharma) |
| TTK Healthcare | ₹1,313 cr | ₹929 | 19.1 | ~1.2× | 6.3% | 8.0% | low | (diversified) |
Reading it: Cupid earns the best return ratios of the three — its core economics genuinely beat both peers. That’s the bull’s relative point. But on price it is off the chart: ~220× earnings and ~53× book, against a high-quality pharma major at ~50× and a consumer-health name at ~19×. Even granting Cupid the best returns and fastest growth, the relative valuation does not rescue the absolute one — there is no peer in this neighbourhood at anything close to Cupid’s multiple. Mankind, with a vastly larger and more diversified franchise (and the Manforce condom brand outright), trades at less than a quarter of Cupid’s P/E. The patient value-investor and the sector-allocator agree here for once: the business is the best of the set; the price is the worst.
Latest quarter & what’s happening now
Q4 FY26 (reported ~15 May 2026): revenue ₹120 cr (+112% YoY), net profit ₹36 cr (+215% YoY). Full-year FY26: revenue ₹358 cr (+95%), PAT ₹108 cr (+165%) — comfortably beating management’s own guidance [HARD]. OPM 31–33%; RoCE jumped to 33.5% from 17%. But other income (₹34 cr for the year) and treasury gains flatter the bottom line, and operating cash flow (₹46 cr) lags PAT.
Live catalysts: the ₹331 cr Baazar Style Retail investment (₹83 cr deployed, ₹150 cr of incremental FY27 revenue claimed) [MEDIUM]; FY27 guidance of ₹600 cr revenue / ₹180 cr PAT [MEDIUM]; new Palava capacity and a South African female-condom tender eligibility [MEDIUM/HARD]; promoter open-market buying through 2026 [HARD]. Institutional holding has fallen to ~1–2% — the rally is retail-driven. Q4 FY26, reported ~2026-05-15.
Where the two lenses agree — and disagree
They agree on the spine: a genuine narrow moat, excellent current return ratios, a real tailwind, low debt — and a price that is indefensible on any disciplined arithmetic (QGLP Price pillar 0/2; Buffett test 8 FAIL).
They disagree in emphasis, and that’s the signal. QGLP’s checklist, being number-driven, is seduced by the spectacular trailing ratios and gives Quality a strong 8/12. The Buffett lens is harsher precisely where a checklist is blind — it fails capital allocation (test 4) and is uneasy on candor and predictability (tests 5–7) because a great boat is being steered toward a worse boat (fashion retail) by a financier with three years at the helm. Trust the Buffett flag. The divergence says: the trailing numbers are real, but the quality of the people deploying them is the open question, and that is what separates an Enduring wealth creator from a Transitory one. Cupid currently tilts Transitory + Volatile.
The price as a current phenomenon
This section judges the price, not the business — the business verdict above is already settled.
The margin-of-safety band. To satisfy QGLP’s Price pillar (PEG ≤ 1 on ~30% growth, or a 5-yr payback ≤ 1×), Cupid would need to trade around ₹15–₹35 — roughly one-fifth to one-twelfth of today’s ₹177. Even on a heroic, sustained 40–50% growth assumption and a premium 35–40× exit multiple, you struggle to justify much above the low end of that band today. The arithmetic is not close.
Mr. Market’s mood. Today the crowd is greedy/euphoric on this name. The shares are up ~700% in a year; the stock is celebrated as “India’s largest FMCG by market cap” (a statistic that says more about the price than the business); the shareholder count octupled to 2.1 lakh as retail piled in, while FIIs who took the warrants largely exited and institutional ownership fell toward 1–2%. That is the classic shape of a story-stock late in its run: smart money leaving, retail arriving, narrative outrunning numbers. Even a sympathetic broker has downgraded it to “Hold on valuation.”
The tension, stated plainly. A wonderful business can sit at an unwonderful price, and a gruesome one can be a bargain. This is firmly the first case, in an extreme form: a Good (occasionally Great) little business at a price that assumes flawless, decade-long, 40%+ compounding and perfect capital allocation by a three-year-old management team. Remember: this price reading can halve next month without one condom going unsold and without one line of the business verdict changing.
Conviction texture
The bull case, at its strongest: Cupid owns a genuinely rare asset — the world’s only dual WHO/UNFPA-prequalified condom maker, with USFDA clearance and IVD optionality — earning 30%+ on capital with a tiny asset base, riding a low-penetration tailwind, run by a hungry promoter putting his own cash in. The FMCG and IVD pivots opened real new runways; FY26 blew past guidance. If the new lines compound and the capital is deployed well, today’s nosebleed multiple could grow into a merely-rich one. This is a real business, not a fraud.
The bear case, at its strongest: You are paying ~220× earnings and ~53× book for a ₹108 cr-profit company whose profit was flat two years ago, is flattered by other income, and doesn’t reliably convert to cash. The management — at the wheel three years — is steering ₹331 cr of owners’ equity into an unrelated fashion retailer and raised ₹385 cr for an acquisition that hasn’t landed as described. FIIs are leaving; retail is arriving. The moat is narrow and the structure (tenders, working capital) is lumpy. At this price, almost any stumble — a slow B2C ramp, a sour retail bet, a tender slipping a quarter — could halve the stock. This is what “priced for perfection” looks like.
What the numbers actually support: a Good business worth owning as a business — at a small fraction of today’s price. The quality is real; the price is the problem; and the management’s capital allocation is the swing factor between Transitory and Enduring.
The two or three things to watch that would tip it: (1) does the Baazar Style money earn the core’s returns and get disclosed cleanly; (2) does operating cash flow finally back the profit; (3) does the B2C range hold margin against the giants. No buy/sell here — just: the boat is fine, the seat is dear, and the captain is unproven.
Sources
- Screener snapshot: https://www.screener.in/company/CUPID/consolidated/ (fetched 2026-06-20)
- Annual reports FY24, FY25 (BSE filings); concalls Q2/Q3 FY24 (Nov 2023, Jan 2024)
- Promoter takeover & ₹159 cr to outgoing promoters: https://www.prnewswire.com/in/news-releases/cupid-rings-in-a-new-management-outgoing-promoters-received-rs-159-crores-301965333.html
- Promoter open-market buying 2026: https://www.indiaipo.in/news/detail/cupid-promoter-aditya-halwasiya-acquires-800000-shares-increases-holding-to-4585 ; https://aninews.in/news/business/aditya-kumar-halwasiya-strengthens-his-stake-in-cupid-limited…20260209151257/
- Baazar Style Retail ₹331.53 cr investment: https://www.tribuneindia.com/news/business/cupid-limited-makes-strategic-investment-of-inr-331-53-cr-in-baazar-style-retail-limited… ; https://www.equitybulls.com/category.php?id=368663
- Q4/FY26 results & FY27 target: https://www.marketsmojo.com/news/result-analysis/cupid-ltd-q4-fy26-spectacular-215-profit-surge-masks-valuation-concerns-3994713 ; https://scanx.trade/stock-market-news/companies/cupid-limited-targets-600-crore-revenue-and-180-crore-net-profit-by-fy27-backed-by-style-baazar-ecosystem/40422205
- Valuation/downgrade & 4:1 bonus (Mar 2026): https://www.marketsmojo.com/news/stock-recommendation/cupid-ltd-downgraded-to-hold-by-marketsmojo-amid-valuation-concerns-3806815
- Peers: Mankind Pharma & TTK Healthcare screener snapshots (fetched 2026-06-20)
- Assumptions: CoE 12%; PAT CAGR 30% used for payback/PEG (lumpy history noted).